Todays Report: The 4,600 Shares of Endocyte Inc. (ECYT) are sold by California Public Employees Retirement System

The 4,600 Shares of Endocyte Inc. (ECYT) are sold by California Public Employees Retirement System

California Public Employees Retirement System reduced its stake in shares of Endocyte Inc. (NASDAQ:ECYT) by 3.1% during the second quarter, Holdings Channel reports. The fund owned 145,800 shares of the biopharmaceutical company’s stock after selling 4,600 shares during the period. California Public Employees Retirement System owned approximately 0.35% of Endocyte worth $468,000 as of its most recent filing with the SEC.

A number of other hedge funds have also modified their holdings of the stock. Concannon Wealth Management LLC raised its stake in shares of Endocyte by 6.5% in the second quarter. Concannon Wealth Management LLC now owns 32,639 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 2,000 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Endocyte by 2.4% in the second quarter. Bank of New York Mellon Corp now owns 152,012 shares of the biopharmaceutical company’s stock valued at $488,000 after buying an additional 3,561 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Endocyte by 2.5% in the first quarter. Geode Capital Management LLC now owns 245,677 shares of the biopharmaceutical company’s stock valued at $761,000 after buying an additional 6,022 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Endocyte by 23.9% in the first quarter. Renaissance Technologies LLC now owns 63,400 shares of the biopharmaceutical company’s stock valued at $197,000 after buying an additional 12,239 shares during the last quarter. Finally, Cribstone Capital Management LLC raised its stake in shares of Endocyte by 45.5% in the second quarter. Cribstone Capital Management LLC now owns 47,349 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 14,808 shares during the last quarter. 36.48% of the stock is currently owned by institutional investors.

Shares of Endocyte Inc. (NASDAQ:ECYT) traded down 2.10% during mid-day trading on Friday, hitting $2.80. The stock had a trading volume of 117,511 shares. Endocyte Inc. has a 52-week low of $2.65 and a 52-week high of $5.63. The company’s market cap is $118.34 million. The stock has a 50 day moving average price of $3.05 and a 200-day moving average price of $3.34.

Endocyte (NASDAQ:ECYT) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. Endocyte had a negative return on equity of 24.71% and a negative net margin of 58,957.14%. During the same period in the previous year, the firm posted ($0.25) earnings per share. On average, equities analysts expect that Endocyte Inc. will post ($1.12) earnings per share for the current fiscal year.

Several analysts have commented on the company. Zacks Investment Research raised Endocyte from a “sell” rating to a “hold” rating in a report on Wednesday, August 17th. Credit Suisse Group AG reissued a “buy” rating on shares of Endocyte in a report on Tuesday, July 12th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Endocyte presently has an average rating of “Buy” and an average target price of $8.19.

Endocyte Company Profile

Related posts

Leave a Comment